AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01625481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-V
Description: Seal-V is applied adjunctively to cover the suture lines.
Study NCT00271739 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine Unit (HTU)
Description: This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
Study NCT00271739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: usual diabetes care, as provided by primary care providers
Study NCT02224066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice per day during three months following TAVI
Study NCT02224066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI
Study NCT02669524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IIGI
Study NCT00684567 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
Study NCT00684567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
Study NCT03991442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/Amlodipine
Description: Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
Study NCT03991442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan/Amlodipine
Description: Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
Study NCT02201459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib (Tasigna ®), capsules of 150 mg
Description: Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
Study NCT02201459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna ®), capsules of 150 mg
Description: Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
Study NCT02201459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)
Description: * Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~* Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation.
Study NCT04424849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT-Scan
Description: Chest CT scan on admission to the intensive care unit
Study NCT02656082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
Study NCT00388934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: percutaneous intervention with implantation of drug eluting coronary stent
Study NCT01202877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
Study NCT01202877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PKC412
Description: Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
Study NCT04142242 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Pharmaceutical form: Solution for injection; Route of administration: Intramuscular
Study NCT04142242 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample for assessment of antibody persistence.
Study NCT02669524 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IIGI
Study NCT02669524 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardised liquid meal
Study NCT02669524 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standardised liquid meal
Study NCT02249221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent cell-culture based influenza vaccin
Description: GC3106, 0.5ml, intramuscular, a single dosing at Day 1
Study NCT02249221 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine
Description: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
Study NCT03050034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WIN @ Hospital system
Description: WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).
Study NCT03050034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional monitoring
Description: Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
Study NCT03857672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotic Cognitive Therapy (HYPNOCT)
Description: The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
Study NCT01702779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mechanical ventilation
Description: Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules
Description: As previously published
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buffalo Rule
Description: As previously published
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia
Description: As previously published
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thompson Test
Description: As previously published
Study NCT02918266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Placebo
Description: Scopolamine placebo-matching subcutaneous injection
Study NCT03014635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Description: Intramuscular injection
Study NCT02918266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071 Placebo
Description: TAK-071 placebo-matching DIC
Study NCT03014635 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Intramuscular injection
Study NCT00107575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment plus brief alcohol intervention
Description: Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palpation of the fibula
Description: Palpation of the fibula over its entire length.
Study NCT02918266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Placebo
Description: Donepezil placebo-matching over-encapsulated tablet
Study NCT02389816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT02389816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study NCT01000194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: A high fat milkshake containing 55g of fat
Study NCT00791440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy
Description: Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
Study NCT00791440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Psychiatric Treatment
Description: Standard psychiatric treatment.
Study NCT06163456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute submaximal exercise
Description: 30 min of treadmill running at 70% of the participants maximal oxygen consumption
Study NCT06163456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute submaximal exercise
Description: 30 min of treadmill running at 70% of the participants maximal oxygen consumption
Study NCT06023173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep radiomics-based fusion model
Description: This multi-modal deep radiomics model, using PET/CT, clinical and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favorable approach for precise patient treatment.
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + palpation of the cuboid bone
Description: As previously published
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + palpation over the deltoid ligament
Description: As previously published
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Malleolar Zone Algorithm
Description: As previously published
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Risk Exam
Description: As previously published
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bernese Ankle Rules
Description: As previously published
Study NCT01205841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ottawa Ankle and Foot Rules + swelling of the distal fibula
Description: As previously published
Study NCT04651322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: upper robot Robot assisted upper arm training(RAT)
Description: The training group received an additional upper robot Robot assisted upper arm training(RAT) with Armeopower® 5 times per week for 4weeks.~\*Robot Assisted Arm training + Conventional occupational therapy
Study NCT04651322 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional therapy
Description: The control group received the usual conventional therapy \*Only Conventional occupational therapy
Study NCT02814968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT02814968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18-FDG PET/CT
Study NCT02814968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body MRI
Study NCT02814968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone scan
Study NCT02778750 — intervention group
Intervention type: PROCEDURE
Intervention: Two-Bronchoscope Technique
Description: Used to validate the use of sputum to sample the lower airway microbiome
Study NCT01182116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: J Pouch
Description: Comparing J pouch, side to end coloanal surgery
Study NCT00837499 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Interview and survey during visit or by phone, 30 - 40 minutes.
Study NCT04326673 — intervention group
Intervention type: OTHER
Intervention: Testosterone Measurements in healthy volunteers after fasting
Description: salivary testosterone measurements taken in morning and evening and a single blood test for testosterone taken
Study NCT04326673 — intervention group
Intervention type: OTHER
Intervention: Testosterone Measurements after glucose loading
Description: salivary tstosterone and blood testosterone measurements
Study NCT02893358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil
Description: Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
Study NCT03119363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AYO light glasses (Experimental)
Description: The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
Study NCT03119363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AYO light glasses (Comparator)
Description: The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
Study NCT04612894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Apatinib
Description: All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
Study NCT04612894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Perform surgery if operable after neoadjuvant therapy
Study NCT04612894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core needle biopsy
Description: Perform core needle biopsy if inoperable after neoadjuvant therapy
Study NCT00623506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)
Study NCT00623506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)
Study NCT02379546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
Study NCT02379546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
Study NCT02379546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index monitoring
Description: Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
Study NCT02379546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index monitoring
Description: Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
Study NCT01725854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response training
Description: Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
Study NCT01936753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trained Mentor Mother and Supervisor
Description: Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
Study NCT05218837 — intervention group
Intervention type: OTHER
Intervention: Vaginal birth
Description: Obstetric anal sphincter injury occurs at the final stage of vaginal delivery.
Study NCT06405867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping (> 60 sec)
Description: In the DCC group, cord pulse was checked without allowing clamping. Waited until the cord pulse stopped. It was wrapped in a sterile and warm cloth and dried. The cord was clamped when the pulse stopped. The cord clamping time was noted on the case report form. In DCC, the baby was placed on the mother's legs in cesarean section (C/S) births and on the mother's mons pubis region in normal vaginal births. The baby was administered a routine delivery room neonatal resuscitation program (NRP) by the pediatrician. After cord clamping, the baby was handed over to the pediatric team.
Study NCT03003988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Description: Creatine monohydrate (6.0 g) + dextrose (0.5 g)
Study NCT03003988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine nitrate
Description: Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
Study NCT03003988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (6.5 g dextrose)
Study NCT02882230 — intervention group
Intervention type: DRUG
Intervention: prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir
Description: chemical dosage ARV
Study NCT02899286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-BCT-100
Description: PEGylated recombinant human arginase